NY-WUNDERKIND
6.3.2023 06:02:36 CET | Business Wire | Press release
Wunderkind, the leading performance marketing solution that delivers guaranteed revenue and performance for brands, publishers and advertisers, announced the appointment of Bill Ingram, a proven marketing technology leader, as Chief Executive Officer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230302005559/en/
Former Adobe and Cheetah Digital executive Bill Ingram named CEO of leading performance marketing solution Wunderkind. (Photo: Business Wire)
Ingram brings over 30 years of experience scaling tech start-ups, leading enterprise SaaS organization advancement, and driving product development and growth. Before joining Wunderkind, Ingram served as President and Chief Product Officer at Cheetah Digital, driving the global innovation and advancement of next generation B2C marketing automation solutions. Previously, Ingram was Vice President and General Manager at Adobe, overseeing the organization’s Analytics Cloud worldwide business for over 10 years. Ingram previously held leadership roles with several SaaS organizations, including Sybase and Omniture, which was acquired by Adobe for $1.8B.
In his role as CEO, Ingram will establish and drive Wunderkind’s strategic direction and product expansion in support of increasing customer engagement for the world’s leading brands. He will focus on taking Wunderkind’s products and services to new levels, while maintaining an industry leading revenue guarantee. Additionally, he will work to advance Wunderkind’s product suite for leading publishers to further engage consumers in an impactful, non-intrusive way that fosters increased brand visibility and qualified engagement. Ingram will lead the team towards ensuring Wunderkind’s solutions continue to help advertisers reach their priority audiences while delivering a quality user experience across a network of premium publishers. Furthermore, he will concentrate on leading the Wunderkind team to eclipsing its over 34% year-over-year revenue increase realized last year.
“Wunderkind has achieved exponential growth by delivering undeniable marketing performance and increased revenue for the world’s most renowned eCommerce brands, who are constantly competing to attract, retain and convert valued customers,” said CEO Bill Ingram. “Wunderkind has proven that channels once perceived as top- and middle-of-funnel can be transformed into significant revenue drivers. I look forward to leading the company’s all-star team as we embark upon a new chapter of strategic innovation and proliferation.”
Ingram’s appointment comes as Wunderkind is poised for continued acceleration in 2023 on the heels of major milestones in 2022, which included: a $76M in Series C financing led by Neuberger Berman; 34% year-over-year revenue gain; and the opening of offices in Australia, Canada, and the Netherlands to further its global reach.
“In a fiercely competitive eCommerce landscape, marketers are under tremendous pressure to deliver verifiable ROI for every dollar spent. Wunderkind's pioneering solutions stand superior to all other solutions in our industry, assisting countless brands in driving provable revenue while building lasting customer loyalty,” said Stephen Collins, Wunderkind’s Board Chairman. “We are confident that Bill’s proven leadership, industry expertise, and success in scaling global technology organizations will realize a new era of growth and success for Wunderkind’s customers, partners and employees alike.”
During the 2022 holiday season, despite a challenging macroeconomic climate, Wunderkind was pivotal in helping its clients achieve more than $1B in directly attributable revenue. The company recently added a host of premium publishers and global retailers to its client roster, including; Rag & Bone, Refinery29, JLo Beauty, Uniqlo, e.l.f. cosmetics, Swatch, Outdoor Voices, See's Candy.
About Wunderkind
Wunderkind is a leading performance marketing solution that drives guaranteed revenue for brands, publishers, and advertisers. As first-party data becomes central to efficient growth, Wunderkind enables brands to identify their website visitors on an individual level and deliver more of their highest-performing, one-to-one messages through websites, emails, texts, and ads than otherwise possible. Wunderkind drives $5 billion annually in directly attributable revenue for brands like Uniqlo, Refinery29, Sonos, and HelloFresh, often ranking as a top three performance channel in their own analytics platforms. Discover how Wunderkind can drive efficient growth for your brand by visiting wunderkind.co.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230302005559/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom